Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Provectus Biopharmaceuticals Inc (PVCT)

Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy

KNOXVILLE, Tenn., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of independent preclinical...

PVCT : 0.0620 (-2.82%)
Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer

KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its...

PVCT : 0.0620 (-2.82%)
Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer

PVCT : 0.0620 (-2.82%)
Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders

PVCT : 0.0620 (-2.82%)
Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs

PVCT : 0.0620 (-2.82%)
VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics

KNOXVILLE, TN / ACCESSWIRE / January 14, 2025 / VisiRose Inc. ("VisiRose" or the "Company"), a privately-held, clinical-stage biotechnology company developing novel ocular therapeutics, today announced...

PVCT : 0.0620 (-2.82%)
VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics

KNOXVILLE, TN / ACCESSWIRE / January 14, 2025 / VisiRose Inc. ("VisiRose" or the "Company"), a privately-held, clinical-stage biotechnology company developing novel ocular therapeutics, today announced...

PVCT : 0.0620 (-2.82%)
Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology

PVCT : 0.0620 (-2.82%)
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals

PVCT : 0.0620 (-2.82%)
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals

PVCT : 0.0620 (-2.82%)

Barchart Exclusives

As Meta Delays New Ray-Ban Display Glasses, Should You Buy, Sell, or Hold META Stock?
Meta’s pause on the global rollout of its Ray-Ban Display smart glasses leaves investors to weigh whether META is a buy, sell, or hold at this pivotal moment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar